What Can Payers Do to Improve Biosimilar Uptake? Ryan Haumschild, PharmD, Weighs In

Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, explains how payers can play an essential role in improving biosimilar adoption at the Academy of Managed Care Pharmacy's annual meeting in Chicago, Illinois.

Transcript:

What more should payers being doing to improve biosimilar uptake and adoption?

Haumschild: Our payer colleagues are so essential to what we do and I think they understand the value of biosimilars. And I think the more you can leverage biosimilars as a preferred agent by the plan, you can reduce total cost of care, you can create some flexibility to health care providers to choose the best biosimilar for them, as long as they know a biosimilar is going to be the preferred treatment, and then continue to leverage real world evidence of biosimilar use so we can continue to expand that rollout across many different practice settings.